RhoGDIβ-induced hypertrophic growth in H9c2 cells is negatively regulated by ZAK by Huang, Chih-Yang et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Journal of Biomedical Science
Open Access Research
RhoGDIβ-induced hypertrophic growth in H9c2 cells is negatively 
regulated by ZAK
Chih-Yang Huang†1,2,3, Li-Chiu Yang†4,5,6, Kuan-Yu Liu†4, Pao-Hsin Liao4,6, 
Janet Ing-Yuh Chou7, Ming-Yung Chou4,6, Wei-Wen Lin8 and Jaw-Ji Yang*4
Address: 1Graduate Institute of Chinese Medical Science, China Medical University, Taichung 404, Taiwan, 2Graduate Institute of Basic Medical 
Science, China Medical University, Taichung 404, Taiwan, 3Department of Health and Nutrition Biotechnology, Asia University, Taichung 413, 
Taiwan, 4School of Dentistry, Chung-Shan Medical University Hospital, Taichung 402, Taiwan, 5Institute of Medicine, Chung-Shan Medical 
University Hospital, Taichung 402, Taiwan, 6Chung-Shan Medical University Hospital, Taichung 402, Taiwan, 7Midwestern University Chicago 
College of Osteopathic Medicine, Chicago, USA and 8Cardiovascular Center, Veterans General Hospital, Taichung 407, Taiwan
Email: Chih-Yang Huang - cyhuang@mail.cmu.edu.tw; Li-Chiu Yang - yang5041@csmu.edu.tw; Kuan-Yu Liu - KYLiu@imb.sinica.edu.tw; Pao-
Hsin Liao - sib01320@seed.net.tw; Janet Ing-Yuh Chou - jichou@excite.com; Ming-Yung Chou - myc@csmu.edu.tw; Wei-
Wen Lin - weilin@vghtc.gov.tw; Jaw-Ji Yang* - jjyang@csmu.edu.tw
* Corresponding author    †Equal contributors
Abstract
We found that overexpression of RhoGDIβ, a Rho GDP dissociation inhibitor, induced
hypertrophic growth and suppressed cell cycle progression in a cultured cardiomyoblast cell line.
Knockdown of RhoGDIβ expression by RNA interference blocked hypertrophic growth. We
further demonstrated that RhoGDIβ physically interacts with ZAK and is phosphorylated by ZAK
in vitro, and this phosphorylation negatively regulates RhoGDIβ functions. Moreover, the ZAK-
RhoGDIβ interaction may maintain ZAK in an inactive hypophosphorylated form. These two
proteins could negatively regulate one another such that ZAK suppresses RhoGDIβ functions
through phosphorylation and RhoGDIβ counteracts the effects of ZAK by physical interaction.
Knockdown of ZAK expression in ZAK- and RhoGDIβ-expressing cells by ZAK-specific RNA
interference restored the full functions of RhoGDIβ.
Background
ZAK belongs to the mixed lineage kinases, a family of ser-
ine/threonine kinases that are classified as MAP3Ks and
can activate the JNK and nuclear factor κB (NFκB) path-
way [1]. ZAK induces JNK activation through a dual phos-
phorylation kinase, JNKK2/MKK7 [2]. To identify
effectors of ZAK and to study the ZAK signaling cascade,
we used a yeast two-hybrid system to isolate ZAK effectors
from a human heart cDNA library. One of the isolated
cDNAs encoded Rho GDP dissociation inhibitor beta
(RhoGDIβ). RhoGDIβ, also known as Ly-GDI or D4-GDI,
belongs to a family of Rho GDP dissociation inhibitors [3-
5] that includes RhoGDIα, RhoGDIβ, and RhoGDIγ [6,7]
and is thought to regulate the activity and localization of
Rho family proteins [8-11]; however, only their ability to
sequester RhoGTPases is well understood. RhoGDIs regu-
late RhoGTPase activity by inhibiting GDP dissociation,
maintaining RhoGTPases in an inactive state. RhoGDIα is
expressed in all cell types and appears to function as a
molecular chaperone for GTPases, shuttling them
between the cytosol and the plasma membrane [12].
Therefore, the question remains as to whether RhoGDIβ is
actually a RhoGTPase regulator. A recent study indicated
that stimulation of T lymphocytes and myelomonocytic
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cells with phorbol esters leads to RhoGDIβ phosphoryla-
tion on serine/threonine residues [13], raising the ques-
tion of whether RhoGDIβ is involved in a signal
transduction pathway in these cells. Thus, details of the
regulatory roles of RhoGDIβ remain to be elucidated.
In the present study, we provide evidence that ZAK serves
as a RhoGDIβ kinase, and demonstrate the phosphoryla-
tion of RhoGDIβ by ZAK in vitro, as well as the physical
association between ZAK and RhoGDIβ. We further show
that this phosphorylation negatively regulates RhoGDIβ-
induced hypertrophic growth. Therefore, we speculate
that the ZAK-RhoGDIβ interaction maintains ZAK in a
hypophosphorylated inactive form.
Materials and methods
Immunoprecipitation and detection of ZAK kinase activity
293T cells were transfected with the ZAK expression vec-
tor, and cell lysates were prepared in IP buffer (40 mM
Tris-HCl, pH 7.5, 1% (w/v) Nonidet P-40 (NP40), 150
mM NaCl, 5 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM
phenylmethylsulfonyl (PMSF), 20 mM NaF, proteinase
inhibitors (1 mg/ml Leupeptin, 1 mg/ml Pepstatin A, 2.5
mg/ml Aprotinin) (Sigma), and 1 mM sodium vanadate).
Cell extracts (200 μg) were incubated with 5 μl of anti-
ZAK polyclonal antibody generated in our laboratory for
6 h at 4°C, mixed with 20 μl of protein-A Sepharose sus-
pension, and incubated for an additional hour. Immuno-
precipitates were collected by centrifugation and washed
three times with IP buffer and twice with kinase buffer (20
mM Tris-HCl, pH7.4, 4 mM MgCl2) alone. Protein kinase
assays were carried out using a GST-RhoGDIβ fusion pro-
tein as the substrate. The GST-RhoGDIβ fusion protein
was incubated for 15 min at 25°C with immunoprecipi-
tated ZAK in the presence of kinase buffer (20 mM HEPES,
pH 7.6, 1 mM EGTA, 1 mM (DTT), 2 mM MgCl2, 2 mM
MnCl2, 5 mM NaF, 1 mM Na3VO4, 50 mM NaCl) and [γ-
32P]ATP. Following incubation, the phosphorylated GST-
RhoGDIβ was boiled in SDS sample buffer, and the pro-
teins were subjected to SDS-PAGE on a 15% gel. The gel
was dried, and phosphorylated RhoGDIβ substrate was
visualized by autoradiography.
Pull-down assay
293T cells were transfected with the pEGFPC1 ZAK
mutant constructs described above. Cell lysates were pre-
cleared with glutathione-Sepharose beads, followed by
the addition of glutathione-Sepharose beads bound to
GST-RhoGDIβ and incubation with rotation for at least 2
h at 4°C in pull-down (PD) buffer (50 mM Tris-HCl, pH
8.0, 150 mM NaCl, 0.5% NP40, 1 mM DTT, 1 mM PMSF,
and protease inhibitor mixture). The beads were washed
five times with PD buffer and boiled for 5 min in 30 μl of
5× concentrated Laemmli buffer. The bound proteins
were then resolved by electrophoresis on 10% SDS-PAGE
gels, followed by immunoblotting.
SiRNA knockdown
We used the expression vector pCDNA-HU6, a derivative
of pCDNA3.1/Myc-His(-) with a human U6 promoter, for
expression of short hairpin RNAs (shRNAs). Two oligonu-
cleotides, shRNA-F (36 nucleotides) and shRNA-R (41
nucleotides), were synthesized, each of which consisted of
a 19-nucleotide stem sequence. The oligonucleotides used
for shRNA were as follows: ZAK460iF
(GATCCGCCTCTCGGTTCCATAACCATTTCAAGAGAA),
ZAK460iR (AGCTTAAAAAGCCTCTCGGTTCCATAAC-
CATTCTCTTGAAA), ZAK1712iF (GATCCGCCAGTGGT-
TAGATACTCTGATTCAAGAGAT), ZAK1712iR
(AGCTTAAAAAGCCAGTGGTTAGATACTCTGATCTCTT-
GAAT), RhoGDIβ353iF (GATCCGGGATATTGTGTCAG-
GCCTGATTCAAGAGAT), RhoGDIβ353iR (AG CTT
AAAAAGGGATATTGTGTCAGGCCTGATCTCTTGAAT),
RhoGDIβ568iF (GATCCGCTGGGAGTGGAACCTGTC-
GATTCAAGAGAT), and RhoGDIβ568iR (AGCTTA
AAAAGCTGGGAGTGGAACCTGTCGATCTCTTGAAT).
Stable RhoGDIβ -or ZAK-expressing H9c2 cell lines were
transfected with these pCDNA-HU6-shRNA plasmids and
a pBABE-puro plasmid as a selection marker. Puromycin-
resistant clones were further tested for expression of ZAK
or RhoGDIβ after addition of doxycycline to induce
expression.
Cell staining and measurement and growth
H9c2 cells were fixed and permeabilized. Actin filaments
were visualized using rhodamine-labeled phalloidin.
Cells were examined and photographed using a Zesis Axi-
oskop and a confocol microscope. The cell size was ana-
lyzed using Image-Pro Plus software.
To determine cell growth, cells were grown in plated on 6-
well dish (5 × 103/well) with the presence of doxycycline
to induce the ectopic genes. Cells were count every 24
hours by hemacytometer.
Results
Isolation of a ZAK-interacting protein, RhoGDI
A fusion protein containing the GAL4 DNA binding
domain and ZAK was used as bait in a yeast two-hybrid
screen for proteins that associate with ZAK from a human
heart cDNA library, as ZAK is highly expressed in heart tis-
sue. Eighty-one clones that specifically interacted with the
bait were identified. Restriction enzyme and nucleotide
sequence analysis revealed that two of these clones con-
tained a 1.3-kb cDNA with a 127-amino acid open read-
ing frame. The cDNA was amplified by RT-PCR and found
to encode the 204-residue human protein RhoGDIβ.
Interaction between ZAK and RhoGDI
To test whether ZAK and the RhoGDIβ identified by the
yeast two-hybrid screen interact in vitro, we performed
pull-down assays with green fluorescent protein (GFP)-
tagged ZAK and glutathione S-transferase (GST)-taggedJournal of Biomedical Science 2009, 16:11 http://www.jbiomedsci.com/content/16/1/11
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RhoGDIβ. We observed that GST-RhoGDIβ interacted
with ZAK, a dominant-negative (dn) ZAK, and a constitu-
tively active (E/E) ZAK (Fig. 1A). We also demonstrate that
RhoGDIβ binding to ZAK may be mediated through a
region encompassing residues 600–700 (Additional file
1) of ZAK. Furthermore, the fragment corresponding to
this region of amino acids 600–700 in ZAK (ZAK 6–7)
was pulled down with GST-RhoGDIβ (Additional file 2),
suggesting that the binding site for RhoGDIβ is between
residues 600–700. Taken together, these data indicate that
ZAK physically interacts with RhoGDIβ  through the
region encompassing residues 600–700, and that this
interaction is independent of the kinase activity of ZAK, as
the kinase-dead mutant (ZAKdn) was pulled down by
GST-RhoGDIβ. We also demonstrated that the relative
Differential binding of ZAK to RhoGDIβ and phosphorylation by ZAK Figure 1
Differential binding of ZAK to RhoGDIβ and phosphorylation by ZAK. 293T cells were transiently transfected with 
the indicated GFP-tagged wild-type or mutant ZAK. After 48 h, cell lysates were harvested and 300 μg of total lysate was used 
in a pull-down assay with glutathione-Sepharose bead-bound GST-RhoGDIβ. (A) Wild-type ZAK (ZAK), dominant-negative 
(dn) ZAK, or constitutively active (E/E) ZAK. Bottom panel shows the binding affinity of RhoGDIβ to different forms of ZAK. 
The relative binding affinity was calculated by the amount of bound form divided by the total loading of RhoGDIβ. (B) Binding 
of RhoGDIβ to ZAK may maintain ZAK in a hypophosphorylated, inactive state. Unbound (U) ZAK in cell lysates consisted of 
both hyperphosphorylated (ppZAK) and hypophosphorylated (pZAK) forms. The hypophosphorylated form of ZAK was 
pulled down by GST-RhoGDIβ. (C) ZAK induces autophosphorylation and phosphorylation of GST-RhoGDIβ. Cell lysates 
from 293T cells transfected with pEGFPC1 empty vector (C), wild-type ZAK (ZAK), or dominant-negative ZAK (dn) were 
immunoprecipitated with anti-GFP. The immunopurified ZAK or ZAKdn was incubated with GST-RhoGDIβ in the presence of 
[γ-32P]ATP. Data shown are representative of three independent experiments.Journal of Biomedical Science 2009, 16:11 http://www.jbiomedsci.com/content/16/1/11
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binding affinity of RhoGDIβ to ZAKdn is higher than
wild-type ZAK.
We have previously shown that ZAK forms homodimers
via its intrinsic leucine zipper domain in order to activate
the JNK/SAPK pathway [2]. Upon dimerization, ZAK
phosphorylates its dimerized partner, resulting in full acti-
vation of ZAK. The data presented here (Fig. 1B) and pre-
viously indicate that overexpression of ZAK in cells results
in a shift in its mobility by SDS-PAGE as a result of auto-
phosphorylation [2]. Because ZAK might exist in both
unphosphorylated and hyperphosphorylated forms in
vivo, we tested the ability of unphosphorylated and
hyperphosphorylated ZAK to bind RhoGDIβ. When
unbound ZAK was visualized by immunoblotting, both
the unphosphorylated and hyperphosphorylated forms
were detected, but only unphosphorylated ZAK was
pulled down by GST-RhoGDIβ, where -100 and -200 were
the positive and negative binding control, respectively
(Fig. 1B). Thus, our result suggests that RhoGDIβ has a
higher affinity for unphosphorylated ZAK.
Given the observed physical interaction of RhoGDIβ with
ZAK, RhoGDIβ may be a kinase substrate for ZAK. We
therefore investigated the potential for RhoGDIβ to be
phosphorylated in the presence of ZAK. An in vitro kinase
assay demonstrated that wild-type ZAK could phosphor-
ylate RhoGDIβ, but the dominant-negative ZAK could
not. Moreover, autophosphorylation of ZAK was also
detected in this assay (Fig. 1C). Our results demonstrate
that RhoGDIβ is able to both bind to and be phosphor-
ylated by ZAK, suggesting that the function of RhoGDIβ
may be regulated by ZAK.
RhoGDI  induces hypertrophic growth in H9c2 cells
To characterize the biological effects of RhoGDIβ on car-
diac cells, we generated stable H9c2 cardiac cells that
expressed RhoGDIβ under tetracycline-responsive trans-
activator control. In this system, the addition of the tetra-
cycline analog doxycycline induces the expression of
RhoGDIβ. Expression of RhoGDIβ resulted in a marked
increase in actin fiber organization (Fig. 2A), and cell size
increased by approximately 2-fold compared to control
cells (Fig. 2B).
Knockdown of RhoGDI  restores cell size in RhoGDI -
expressing H9c2 cells
To confirm the role of RhoGDIβ in hypertrophic growth
of RhoGDIβ-expressing H9c2 cells, we knocked down
RhoGDIβ expression in these cells by vector-based stable
transfection of small interfering RNAs (siRNAs) specific
for RhoGDIβ. Two target sequences were used, corre-
sponding to nucleotides 353 to 373 (U6-353i) and 568 to
588 (U6-568i). The siRNA-mediated suppression of
RhoGDIβ expression was stable for 60 days (data not
shown). RhoGDIβ knockdown cells were smaller than
RhoGDIβ-overexpressing cells (Fig. 2C) and had less
organized actin fibers (data not shown). These results
demonstrate that RhoGDIβ is able to modulate hyper-
trophic growth in H9c2 cells, and that specific knockdown
of RhoGDIβ decreases the enlarged cell size induced by
RhoGDIβ.
To assess whether the expression of RhoGDIβ in H9c2 car-
diac cells could influence cell cycle progression, we first
set out to determine the growth rate of RhoGDIβ-express-
ing cells compared to parental cells. A total of 5000 cells
ectopically expressing RhoGDIβ were cultured in 6-well
dishes. The RhoGDIβ-expressing cells grew slower than
the parental cells (Fig. 3A). To determine whether the
slower growth of the RhoGDIβ-expressing cells was due to
blocking of the cell cycle, the cell cultures were trypsinized
and their cell cycle distributions were analyzed by flow
cytometry. RhoGDIβ-expressing cells had a higher per-
centage of cells in G1 (78.77%) compared to control cells
(68.50%). Moreover, fewer RhoGDIβ-expressing cells
were in the G2/M and S phases (6.35% and 8.71%, respec-
tively) compared to parental cells (14.88% and 22.78%,
respectively) (Fig. 3B). These results suggest that RhoGDIβ
or its regulated signaling pathways might be involved in
regulation of G1 checkpoint control.
Effects of RhoGDI  on expression of cell cycle regulatory 
proteins
The expression levels of G1 cyclins (cyclin D and E) are
rate-limiting for cell cycle progression [14]. However, by
western blot analysis, neither cyclin D nor E levels were
changed in the low proliferative capacity RhoGDIβ-
expressing cells (Fig. 3C). Because cell cycle progression
commences in G1 with assembly and activation of cyclin
D-CDK4/6, followed by the subsequent activation of cyc-
lin E-CDK2 in the G1/S transition, we also studied the
effect of RhoGDIβ on G1 cell cycle regulatory proteins.
RhoGDIβ expression also had no effect on the activity of
the cyclin D-CDK4/6 complex in H9c2 cells; however, the
kinase activity of cyclin E-CDK2 complexes decreased in
the RhoGDIβ-expressing cells (Fig. 3C). Because the activ-
ities of these CDK complexes can be regulated by the cyc-
lin-dependent kinase inhibitors (CKIs) p21Waf1/Cip1 and
p27Kip1, we measured their expression levels. We deter-
mined that the protein levels of both p21Waf1/Cip1 and
p27Kip1 were increased in the RhoGDIβ-expressing cells
(Fig. 3C). However, the high p21Waf1/Cip1 expression levels
did not decrease the activity of the cyclin D-CDK4/6 com-
plex in these cells. Studies by other investigators have
indicated that elevated CKI expression levels are similarly
associated with vascular smooth muscle [15] and mesang-
ial cell hypertrophy [16]. Our observations suggest that
the level of p21Waf1/Cip1, which is regulated by RhoGDIβ
or its signaling pathways, might play a role in the responseJournal of Biomedical Science 2009, 16:11 http://www.jbiomedsci.com/content/16/1/11
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RhoGDIβ expression in H9c2 cells induces hypertrophic growth Figure 2
RhoGDIβ expression in H9c2 cells induces hypertrophic growth. (A) H9c2 cells stably transfected with empty vector 
(pTet) or pTet-RhoGDIβ were grown in 10% fetal bovine serum with doxycycline for 3 days. The transfected H9c2 cells were 
fixed and immunostained with rhodamine-conjugated phalloidin. (B) Relative cell size was measured after 3 days of growth of 
the transfected H9c2 cells in the presence of doxycycline. (C) Quantification of the cell size of H9c2 RhoGDIβ-expressing cells 
that also expressed RhoGDIβ siRNA (U6-353i or U6-568i) or scrambled siRNA (U6-Ci).Journal of Biomedical Science 2009, 16:11 http://www.jbiomedsci.com/content/16/1/11
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to hypertrophic stimuli. This role, however, appears to be
dissociated from the regulation of cyclin D-CDK4/6 activ-
ity by p21. Furthermore, levels of p27Kip1 were elevated in
RhoGDIβ-expressing cells, and expression was inversely
correlated to the kinase activity of cyclin E-CDK2 (Fig.
3C). These results suggest that expression of p27Kip1 might
be associated with cell proliferation.
RhoGDI -induced hypertrophic growth is regulated by ZAK
Given our finding that RhoGDIβ proteins can associate
with and be phosphorylated by ZAK, we hypothesized
that the function of RhoGDIβ is regulated by ZAK. We
used a bi-directional tetracycline-responsive transactiva-
tor vector to regulate the expression of RhoGDIβ or ZAK
(wt or dn), or both RhoGDIβ and ZAK (wt or dn), in H9c2
cells, and then cell sizes were measured. Consistent with
previous studies [17,18], ZAK-expressing or RhoGDIβ-
expressing cells showed an increase in cell size of approx-
imately 1.7- or 2.5-fold, respectively (Fig. 4A), and also
underwent actin fiber reorganization (data not shown).
The co-expression of both ZAK and RhoGDIβ in H9c2
cells resulted in a decrease in cell size from 2.5-fold to 1.2-
RhoGDIβ expression in H9c2 cells retards cell cycle progression Figure 3
RhoGDIβ expression in H9c2 cells retards cell cycle progression. (A) Growth rate of H9c2 cells stably transfected 
with pTet or pTet-RhoGDIβ grown in 10% fetal bovine serum containing doxycycline. (B) Analysis of RhoGDIβ-expressing 
cells by flow cytometry. RhoGDIβ-expressing H9c2 cells were grown in 10% fetal bovine serum with doxycycline for 3 days, 
and cells were stained with propidium iodide and subjected to flow cytometry. The percentages of cells in the different cell 
cycle phases were calculated using ModFit software. Experiments were performed three times and gave similar results. (C) 
Expression and activities of various regulatory cell cycle proteins in RhoGDIβ-expressing cells. Total cell extract was analyzed 
by western blotting and probing with the specific antibodies indicated. Cyclin D or E was immunoprecipitated from RhoGDIβ-
expressing cells and analyzed for associated histone H1 kinase activity. JNK activity was analyzed by immunoprecipitating JNK 
and assessing its activity using GST-c-jun as a substrate.Journal of Biomedical Science 2009, 16:11 http://www.jbiomedsci.com/content/16/1/11
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fold relative to the parental cells. ZAKdn-RhoGDIβ cells
did not have a substantially decreased cell size relative to
RhoGDIβ-expressing cells (Fig. 4A). These results suggest
that the kinase activity of ZAK might play a negative regu-
latory role in the hypertrophic growth functions of
RhoGDIβ in cardiac cells.
Overexpression of both RhoGDI  and ZAK reverses 
RhoGDI -regulated cell arrest
As the expression of RhoGDIβ induced G1 arrest in H9c2
cells, but expression of ZAK had no effect on cell cycle pro-
gression and ZAK was able to regulate RhoGDIβ func-
tions, we next studied the effects of ZAK on RhoGDIβ's
regulation of cell growth rate by examining the growth
rate in ZAK- and RhoGDIβ-expressing cells compared
with RhoGDIβ-expressing cells. Cells expressing both ZAK
and RhoGDIβ grew substantially faster than RhoGDIβ-
expressing cells (Fig. 4B). Moreover, ZAKdn- and
RhoGDIβ-expressing cells demonstrated the same growth
rate as RhoGDIβ-expressing cells.
To determine the role of ZAK in RhoGDIβ-induced hyper-
trophic growth in H9c2 cells, we compared the cell sizes
of ZAK siRNA-, ZAK- and RhoGDIβ-expressing cells
(ZAKGRi2), scrambled ZAK siRNA-, ZAK- and RhoGDIβ-
expressing cells (ZAKGRCi), and ZAK- and RhoGDIβ-
expressing cells. The expression of ZAK siRNA, but not
scrambled ZAK siRNA, in cells overexpressing ZAK and
RhoGDIβ increased cell size to the same degree as
observed for RhoGDIβ-expressing cells (Fig. 4C).
Discussion
We identified RhoGDIβ as a ZAK-interacting protein in a
yeast two-hybrid screen. This led us to investigate whether
and how they might regulate one another's functions.
RhoGDIα was first identified in bovine brain cytoplasm
on the basis of its ability to inhibit GDP dissociation from
RhoGTPases. RhoGDIβ, the second GDI identified, shares
67% amino acid identity with RhoGDIα and is almost
exclusively expressed in hematopoietic lineages [8]. In
contrast to RhoGDIα, RhoGDIβ might bind to and inhibit
GDP dissociation from purified RhoGTPases in vitro, and
appears to be at least 10-fold less potent than RhoGDIα
[19]. Moreover, it has been reported that RhoGDIβ can be
phosphorylated on tyrosine [20]. Therefore, questions
arise with regard to whether RhoGDIβ is an actual regula-
tor of cellular RhoGTPases, its role in the signaling path-
way, and its regulation. Upon introduction of RhoGDIβ
into rat cardiac H9c2 cells, the cells exhibited hyper-
trophic growth and a retarded cell cycle. We also demon-
strated that RhoGDIβ is phosphorylated by ZAK in vitro. It
is striking that the co-expression of ZAK and RhoGDIβ in
H9c2 cardiac cells resulted in inhibition of the biological
functions of RhoGDIβ, indicating that not only does
RhoGDIβ potentially physically interact with ZAK, but it
may also be negatively regulated by ZAK via phosphoryla-
tion. Several studies have also demonstrated that
RhoGDIβ is cleaved at its N terminus during apoptosis in
a caspase-dependent manner, and that the cleaved
RhoGDIβ is retained in the nuclear compartment [21].
This suggests that RhoGDIβ could function in the nucleus.
Numerous studies have implicated RhoGDIβ phosphor-
ylation/dephosphorylation in the regulation of RhoGT-
Pases/RhoGDIβ complex dissociation and mediation of
RhoGTPase activation [22,23]. We found that RhoGDIβ
was able to associate with a mixed lineage kinase, ZAK,
resulting in phosphorylation of RhoGDIβ. We are cur-
rently mapping the phosphorylation sites of RhoGDIβ. To
further study the role of ZAK in regulating the activity of
RhoGDIβ, we used a bi-directional tet-on inducible sys-
tem to express both ZAK and RhoGDIβ in H9c2 cardiac
cells. Our results demonstrate that the hypertrophic
growth phenotype was inhibited by coexpression of ZAK
and RhoGDIβ; however, we did not observe an inhibitory
effect for the dominant-negative ZAK. Clearly, the kinase
activities of ZAK are necessary for the negative regulation
of RhoGDIβ functions, including G1 cell cycle arrest and
hypertrophic growth.
The physical interaction of ZAK and RhoGDIβ results in
subsequent inactivation of RhoGDIβ by phosphorylation,
and might require docking interactions. The RhoGDIβ
docking domain is localized to the last 100 C-terminal
residues of ZAK. One possible hypothesis is that binding
of ZAK to RhoGDIβ might change the localization and/or
subcellular concentrations of both proteins as well as the
biological functions of ZAK. Interference with the cellular
activities of ZAK by RhoGDIβ, as evidenced by the results
of the pull-down assay, measurements of cell size, and
growth of the transfected cells, might be partially
explained by maintenance of the bound ZAK in a hypo-
phosphorylated form. Comparison of the cell size of ZAK-
expressing cells with ZAK- and RhoGDIβ-expressing cells
showed a relative decrease in cell size of 1.74- to 1.32-
fold. We also found that ZAK kinase activities were
decrease in cells with the co-expression of ZAK and
RhoGDIβ (data not show). In addition, the fact that the
growth rate of ZAK- and RhoGDIβ-expressing cells was
similar to ZAKdn-expressing cells and faster than
RhoGDIβ-expressing cells indicates that RhoGDIβ inhib-
its the biological functions of ZAK.
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ZAK reverses the effects of RhoGDIβ induction of hypertrophic growth, cell migration, and suppression of cell cycle progres- sion in H9c2 cells Figure 4
ZAK reverses the effects of RhoGDIβ induction of hypertrophic growth, cell migration, and suppression of cell 
cycle progression in H9c2 cells. (A) H9c2 cells or H9c2 cells that ectopically expressed ZAK, dominant-negative ZAK 
(ZAKdn), RhoGDIβ, ZAK and RhoGDIβ, or ZAKdn and RhoGDIβ under the control of a bi-directional tetracycline response 
element were grown in 10% fetal bovine serum with doxycycline for 3 days, and cell size was determined. (B) The growth rate 
of the same cells shown in (A) grown in 10% fetal bovine serum with doxycycline. (C) SiRNA knockdown of ZAK restores the 
hypertrophic growth induced by RhoGDIβ in ZAK- and RhoGDIβ-expressing cells (ZAKGRi2).Publish with BioMed Central    and   every 
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Supplementary figure 1. Binding of GST-RhoGDIb in a GST pull-down 
assay with ZAK-6-7. ZAK-100 (-100) is the positive control, and ZAK-
200 (-200) is the negative control.
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Supplementary figure 2. Series of different carboxyl terminal pEGFPc1-
ZAK deletion mutants.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1423-
0127-16-11-S2.tiff]